

MAINTAIN (Mucosal Ablation Therapy After INcretins)

NCT06734312

Status	RECRUITING
Phase	Not Applicable
Sponsor	Dr. Christopher McGowan
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (9)

- Subjects aged 21-65
 - Body mass Index (BMI) ≥ 30 kilograms per square meter (kg/m^2), or $\geq 45 \text{ kg/m}^2$
 - Observed $\geq 10\%$ TBWL with semaglutide or tirzepatide use for primary obesity therapy
 - Subject did not experience $>50\%$ weight recurrence since discontinuation of semaglutide or tirzepatide
 - Maintained a stable dose of semaglutide or tirzepatide for a minimum of 12 weeks
- ... and 4 more (see full listing online)

Exclusion (16)

- Known diagnosis of type I or type II diabetes or a Hemoglobin A1c $> 6.5\%$ at time of screening
 - Use of GLP-1 or GLP-1/GIP medication for the treatment of diabetes, rather than obesity.
 - Use of anticoagulation, antithrombotic agents, and/or NSAIDs that cannot be discontinued for a minimum of 12 weeks
 - Known bleeding diathesis that cannot be corrected through medical means.
 - History of decompensated end-organ disease
- ... and 11 more (see full listing online)

Locations (2 total)

True You Weight Loss, Cary, North Carolina, United States
True You Weight Loss, Cary, North Carolina, United States